Duopharma Biotech Berhad (KLSE:DPHARMA)
Malaysia
· Delayed Price · Currency is MYR 1.500
+0.020 (1.35%)
At close: Mar 6, 2026
Duopharma Biotech Berhad Income Statement
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 931.69 | 813.7 | 704.73 | 696.72 | 639.18 | Upgrade
|
| Revenue Growth (YoY) | 14.50% | 15.46% | 1.15% | 9.00% | 12.16% | Upgrade
|
| Cost of Revenue | 568.56 | 512.16 | 436.4 | 416.9 | 385.19 | Upgrade
|
| Gross Profit | 363.14 | 301.54 | 268.33 | 279.82 | 253.98 | Upgrade
|
| Selling, General & Admin | 227.58 | 202.02 | 182.72 | 186.59 | 165.78 | Upgrade
|
| Other Operating Expenses | 1.77 | 0.7 | 2.8 | 0.81 | -0.67 | Upgrade
|
| Operating Expenses | 229.35 | 201.28 | 189.61 | 186.91 | 165.22 | Upgrade
|
| Operating Income | 133.79 | 100.26 | 78.71 | 92.91 | 88.77 | Upgrade
|
| Interest Expense | -24.75 | -25.77 | -17.68 | -9.1 | -6.44 | Upgrade
|
| Interest & Investment Income | 5.87 | 5.97 | 2.75 | 1.52 | 1.2 | Upgrade
|
| Other Non Operating Income (Expenses) | - | -0.82 | -0.52 | -0.48 | -0.53 | Upgrade
|
| EBT Excluding Unusual Items | 114.91 | 79.63 | 63.27 | 84.85 | 82.99 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.39 | - | - | -0.01 | Upgrade
|
| Pretax Income | 114.91 | 80.02 | 63.27 | 84.85 | 82.98 | Upgrade
|
| Income Tax Expense | 27.45 | 17.38 | 10.62 | 14.74 | 17.3 | Upgrade
|
| Net Income | 87.46 | 62.65 | 52.65 | 70.11 | 65.68 | Upgrade
|
| Net Income to Common | 87.46 | 62.65 | 52.65 | 70.11 | 65.68 | Upgrade
|
| Net Income Growth | 39.62% | 19.00% | -24.91% | 6.74% | 12.07% | Upgrade
|
| Shares Outstanding (Basic) | 962 | 962 | 959 | 948 | 928 | Upgrade
|
| Shares Outstanding (Diluted) | 962 | 962 | 959 | 948 | 928 | Upgrade
|
| Shares Change (YoY) | - | 0.36% | 1.08% | 2.15% | 0.02% | Upgrade
|
| EPS (Basic) | 0.09 | 0.07 | 0.05 | 0.07 | 0.07 | Upgrade
|
| EPS (Diluted) | 0.09 | 0.07 | 0.05 | 0.07 | 0.07 | Upgrade
|
| EPS Growth | 39.58% | 18.57% | -25.71% | 4.50% | 12.05% | Upgrade
|
| Free Cash Flow | 80.08 | 59.77 | 15.86 | 5.08 | -66.16 | Upgrade
|
| Free Cash Flow Per Share | 0.08 | 0.06 | 0.02 | 0.01 | -0.07 | Upgrade
|
| Dividend Per Share | 0.045 | 0.030 | 0.023 | 0.023 | 0.022 | Upgrade
|
| Dividend Growth | 51.67% | 30.44% | - | 5.75% | -55.43% | Upgrade
|
| Gross Margin | 38.98% | 37.06% | 38.07% | 40.16% | 39.74% | Upgrade
|
| Operating Margin | 14.36% | 12.32% | 11.17% | 13.33% | 13.89% | Upgrade
|
| Profit Margin | 9.39% | 7.70% | 7.47% | 10.06% | 10.28% | Upgrade
|
| Free Cash Flow Margin | 8.60% | 7.35% | 2.25% | 0.73% | -10.35% | Upgrade
|
| EBITDA | 179.41 | 137.34 | 114.04 | 122.86 | 114.94 | Upgrade
|
| EBITDA Margin | 19.26% | 16.88% | 16.18% | 17.63% | 17.98% | Upgrade
|
| D&A For EBITDA | 45.62 | 37.08 | 35.32 | 29.95 | 26.18 | Upgrade
|
| EBIT | 133.79 | 100.26 | 78.71 | 92.91 | 88.77 | Upgrade
|
| EBIT Margin | 14.36% | 12.32% | 11.17% | 13.33% | 13.89% | Upgrade
|
| Effective Tax Rate | 23.89% | 21.72% | 16.79% | 17.37% | 20.85% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.